Twentyeight-Seven’s bet on RNA-binding proteins
Twentyeight-Seven is capitalizing on the emerging biology of RNA-binding proteins by targeting their interactions with non-coding RNAs
Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins.
Launched last September, the company is using an $82.8 million series A round backed by a syndicate that includes MPM Capital, Novartis Venture Fund and Sofinnova Partners to advance its lead cancer program and extend its platform to similar targets in other indications, including inflammatory diseases.
By modulating gene